In 688,183 Medicare patients given intravenous iron, the risk of anaphylaxis at first exposure was 68 per 100,000 for iron dextran against 24 per 100,000 for the non-dextran products combined.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
In 688,183 Medicare patients given intravenous iron, the risk of anaphylaxis at first exposure was 68 per 100,000 for iron dextran against 24 per 100,000 for the non-dextran products combined. · pmid:26575062
Serious adverse events with iron dextran have been attributed to its high-molecular-weight preparations; a review argued that low-molecular-weight iron dextran and iron sucrose have similar safety profiles in chronic kidney disease. · pmid:18274543
Identity
No public registry record is shown for this page: PubChem gave no record that proves it is this substance.
Where the evidence actually sits
Established50%
Emerging50%
Proportion of the 2 claims about Iron dextran standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Iron dextran yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. · pmid 26575062 · 2015
Observational evidence· resolved human data at the emerging tier: thin, or contested
Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. · pmid 18274543 · 2008
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.